Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Post Hoc Analysis: Time-From-Diagnosis Subgroups

When Used Within 6 Months of Diagnosis, There Was a 55% Relative Risk Reduction of Disease Progression With UPTRAVI® vs Placebo1

In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 55% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI® WAS USED WITHIN 6 MONTHS OF DIAGNOSIS VS PLACEBO1*

Time to first disease progression event in patients treated within 6 months of PAH diagnosis
Percent of patients treated within 6 months of PAH diagnosis without an event mobile curve
55% risk reduction HR 0.45 (95% CI: 0.33, 0.63)

Baseline patient characteristics

  • GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
    • 35% (n=404) of all patients in GRIPHON were treated ≤6 months from diagnosis (52% FC II and 46% FC III)†
  • 41% were receiving PDE-5i monotherapy, 39% were receiving no background PAH therapy, 10% were receiving ERA monotherapy, and 10% were receiving an ERA + PDE-5i at baseline
  • Mean age: UPTRAVI® (44 years), placebo (44 years)
  • FC II: UPTRAVI® (55%), placebo (49%)

Summary of primary endpoint events in patients treated within 6 months of PAH diagnosis

Events in patients treated within 6 months of PAH diagnosis mobile table

Adverse reactions in ≤6 months from diagnosis subgroup occurring more frequently with UPTRAVI® compared with placebo by ≥3%

Adverse reactions in ≤6 months from diagnosis subgroup notably different from overall population mobile table

The analysis described here is post hoc and exploratory. The subgroup was not prespecified for evaluation of the primary endpoint. Please note this analysis did not compare patients treated within 6 months of PAH diagnosis with patients treated after 6 months of PAH diagnosis. Sample size should be considered and results should be interpreted with caution.

In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 26% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION WHEN UPTRAVI® WAS USED AFTER 6 MONTHS OF DIAGNOSIS VS PLACEBO1*

Time to first disease progression event in patients treated after 6 months of PAH diagnosis
Percent of patients treated after 6 months of PAH diagnosis without an event mobile curve
26% risk reduction HR 0.74 (95% CI: 0.57, 0.96)

Baseline patient characteristics

  • GRIPHON patients were categorized based on their time from diagnosis at baseline using a 6-month threshold:
    • 65% (n=752) of all patients in GRIPHON were treated >6 months from diagnosis (56% FC III, 42% FC II)†
  • 28% were receiving PDE-5i monotherapy, 11% were not receiving PAH background therapy, 17% were receiving ERA monotherapy, and 45% were receiving an ERA + PDE-5i at baseline
  • Mean age: UPTRAVI® (50 years), placebo (50 years)
  • FC II: UPTRAVI® (44%), placebo (41%)
Summary of primary endpoint events in patients treated after 6 months of PAH diagnosis
Events in patients treated within and after 6 months of PAH diagnosis mobile table

Adverse reactions in >6 months from diagnosis subgroup occurring more frequently with UPTRAVI® compared with placebo by ≥3%

Adverse reactions in >6 months from diagnosis subgroup notably different from overall population mobile table

The analysis described here is post hoc and exploratory. The subgroup was not prespecified for evaluation of the primary endpoint. Please note this analysis did not compare patients treated within 6 months of PAH diagnosis with patients treated after 6 months of PAH diagnosis. Sample size should be considered and results should be interpreted with caution.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Concomitant use of strong inhibitors of CYP2C8 (eg, gemfibrozil) with UPTRAVI® is contraindicated.

Hypersensitivity to the active substance or to any of the excipients is contraindicated.

WARNINGS AND PRECAUTIONS

Pulmonary Edema with Pulmonary Veno-Occlusive Disease (PVOD)

Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue UPTRAVI®.

ADVERSE REACTIONS

Adverse reactions more frequent compared to placebo (≥3%) seen with UPTRAVI® Tablets are headache (65% vs 32%), diarrhea (42% vs 18%), jaw pain (26% vs 6%), nausea (33% vs 18%), myalgia (16% vs 6%), vomiting (18% vs 9%), pain in extremity (17% vs 8%), flushing (12% vs 5%), arthralgia (11% vs 8%), anemia (8% vs 5%), decreased appetite (6% vs 3%), and rash (11% vs 8%).

These adverse reactions are more frequent during the dose titration phase.

Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI® Tablets and in none of the patients on placebo.

DRUG INTERACTIONS

CYP2C8 Inhibitors

Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant use of UPTRAVI® with strong inhibitors of CYP2C8 is contraindicated.

Concomitant administration of UPTRAVI® with clopidogrel, a moderate inhibitor of CYP2C8, had no relevant effect on the exposure to selexipag and increased the exposure to the active metabolite by approximately 2.7–fold. Reduce the dosing of UPTRAVI® to once daily in patients on a moderate CYP2C8 inhibitor.

CYP2C8 Inducers

Concomitant administration with an inducer of CYP2C8 and UGT 1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase UPTRAVI® dose, up to twice, when co-administered with rifampin. Reduce UPTRAVI® when rifampin is stopped.

DOSAGE AND ADMINISTRATION

Recommended Dosage

Recommended starting dose is 200 mcg twice daily for UPTRAVI® Tablets. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose.

Patients With Hepatic Impairment

For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of UPTRAVI® Tablets is 200 mcg once daily. Increase by 200 mcg once daily at weekly intervals, as tolerated. Avoid use of UPTRAVI® in patients with severe hepatic impairment (Child-Pugh class C).

Co-administration With Moderate CYP2C8 Inhibitors

When co-administered with moderate CYP2C8 inhibitors (eg, clopidogrel, deferasirox and teriflunomide), reduce the dosing of UPTRAVI® to once daily.

Dosage Strengths

UPTRAVI® tablet strengths:
200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg.

Additional Important Safety Information for UPTRAVI® IV

Use UPTRAVI® for injection in patients who are temporarily unable to take oral therapy.

Administer UPTRAVI® for injection twice daily by intravenous infusion at a dose that corresponds to the patient’s current dose of UPTRAVI® Tablets (see Table 1 in full Prescribing Information). Administer UPTRAVI® for injection as an 80-minute intravenous infusion.

Adverse Reactions: Infusion-site reactions (infusion-site erythema/redness, pain and swelling) were reported with UPTRAVI® for injection.

INDICATION

UPTRAVI® (selexipag) is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Effectiveness of UPTRAVI® Tablets was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.

Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), and PAH associated with congenital heart disease with repaired shunts (10%).

Please see full Prescribing Information for UPTRAVI®.

cp-126160v5

*Not adjusted for multiplicity.

†This threshold has previously been used to define newly diagnosed patients with PAH.

‡Adjusted for the following covariates: baseline PAH therapy, WHO FC, sex, race, age, etiology, geographical region, baseline 6MWD, and NT-proBNP. Not adjusted for multiplicity.

§Hazard ratio based on primary endpoint events up to the end of treatment.

‖Treatment period defined as 7 days after last intake of UPTRAVI® or placebo.

6MWD=6-minute walk distance; CI=confidence interval; ERA=endothelin receptor antagonist; FC=Functional Class; GRIPHON=Prostacyclin (PGI2) Receptor Agonist In Pulmonary Arterial HypertensiON; HR=hazard ratio; NT-proBNP=N-terminal pro-brain natriuretic peptide; PDE-5i=phosphodiesterase type-5 inhibitor; WHO=World Health Organization.

Reference: 1. Gaine S, Sitbon O, Channick RN, et al. Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study. Chest. 2021;160(1):277-286.